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Objectives: To compare the performance of the Accelerate PhenoTM system with that of the conventional
phenotypic VITEKV
R
2 system for rapid antimicrobial susceptibility testing (AST) of bacterial pathogens from posi-
tive blood culture (PBC) samples, based on the reference broth microdilution (BMD) method.
Methods: Prospectively collected PBCs that represented patient-unique bloodstream infection episodes were
included. For PBC samples showing monomicrobial growth (n"86), AST was performed using both Accelerate
PhenoTM and VITEKV
R
2 systems directly from PBC broth. Colony isolates derived from subculture of PBC broth
were then used for BMD testing. AST results were interpreted according to 2017 EUCAST breakpoints.
Results: The overall categorical agreement between Accelerate PhenoTM system and BMD was 92.7% (467/504)
for Gram-negative organisms and 99.0% (95/96) for Gram-positive organisms, with rates for very major errors of
3.6% (6/166), major errors 2.2% (9/416) and minor errors 3.8% (23/600). The overall categorical agreement be-
tween the VITEKV
R
2 system and BMD was 91.7% (463/505) for Gram-negative organisms and 99.0% (97/98) for
Gram-positive organisms, with rates of very major errors of 2.4% (4/169), major errors 1.0% (4/416) and minor
errors 5.8% (35/603). Importantly, unlike the VITEKV
R
2 system, no false-susceptible results occurred with two
colistin-resistant organism-growing PBCs tested using the Accelerate PhenoTM system.
Conclusions: Based on these findings, the Accelerate PhenoTM system can be a valid alternative for the rapid
AST of Gram-negative and Gram-positive bacteria in bloodstream infections.
Introduction
Bloodstream infections (BSIs) remain a major public health con-
cern because of their high incidence and serious consequences in
terms of mortality, morbidity and cost, particularly in the case of
nosocomial infection.1 While timely administration of effective
antimicrobial therapy may reduce hospital length of stay and mor-
tality of patients with a BSI,2–4 delayed (and potentially less effect-
ive) treatment often results in more severe stages of BSI-related
disease.5,6 Of note, drug-resistant and MDR organisms are the
most frequent trigger for sepsis and septic shock—a particularly
serious manifestation of sepsis—thereby requiring initiation of
treatment within 1 h of their detection.7
Antimicrobial susceptibility testing (AST) of organisms causing
BSIs is an undisputed prerequisite for optimal antimicrobial ther-
apy.8 In contrast to conventional automated methods, such as the
widely used VITEKV
R
2 system (bioMérieux, Marcy-l’Étoile, France),9,10
recent efforts have led to the development of new-generation
methods for AST.11–16 Among them is the Accelerate PhenoTM sys-
tem (Accelerate Diagnostics, Tucson, AZ, USA), an automated mi-
croscopy platform that uses fluorescence in situ hybridization for
identification and morphokinetic cellular analysis to provide AST
results (i.e. MIC) directly from positive blood cultures (PBCs);17 blood
culture (BC) remains the gold standard for detection of bacterial and
fungal BSIs.18 The Accelerate PhenoTM system obtained US FDA
clearance in early 2017. Data from the US clinical trial used to sup-
port FDA clearance of the system were recently published.19
Until now, there have been few published studies that have
evaluated the performance of the Accelerate PhenoTM system;20–
24 these evaluations include an assessment of the Accelerate
PhenoTM system for both identification and AST of BSI organisms
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(in either fresh or contrived PBCs), and/or restricted evaluations of
specific organism groups (e.g. Gram-negative bacteria, MDR Gram-
negative bacilli)20,24 or patient populations (i.e. paediatric oncol-
ogy).21 Furthermore, these studies did not use or only partially
used the reference broth microdilution (BMD) method as a com-
parator, in one case to resolve discrepancies between the results
of the Accelerate PhenoTM and VITEKV
R
2 systems. In this prospect-
ive study, we assessed the MIC and categorical agreement (sus-
ceptible, intermediate and resistant) results between the
Accelerate PhenoTM and VITEKV
R
2 systems by rapid testing of PBCs,




The ethics committee of our institution approved this study (approval num-
ber 0044603/17) and waived the requirement for informed consent.
Study design, blood samples and microbial isolates
Prospectively collected PBCs that represented single episodes of BSI
(i.e. only the first PBC per single patient) at a tertiary-care teaching hos-
pital in Rome, Italy, were evaluated over a 6 month period in 2017
(Table S1, available as Supplementary data at JAC Online). We col-
lected blood cultures (BCs) in BacT/ALERTV
R
FA and FN PLUS bottles




system (bioMérieux). For each PBC, organism identification was deter-
mined to the species level using a BSI diagnostic algorithm previously
described.25 Gram staining was performed to distinguish PBCs with
monomicrobial (n"105) or polymicrobial (n"12) growth, which was
followed by direct analysis using the MALDI BioTyperV
R
system (Bruker
Daltonics, Bremen, Germany) and supplemented with the FilmArrayV
R
BC ID panel (bioMérieux). In parallel, we subcultured PBC broths on
standard solid media and incubated them overnight at 35C to yield
colony isolates. MICs were determined by three methods: the
Accelerate PhenoTM system; the VITEKV
R
2 system performed directly
from PBC broth (for samples where only one bacterial morphology was
seen on Gram stain, i.e. presumed to be monomicrobial) or colony iso-
lates (for samples demonstrating more than one Gram stain morph-
ology, i.e. polymicrobial); and BMD.26 For VITEKV
R
2 system testing using
PBC broth as inoculum, we subjected PBC broths to a brief pre-
treatment (i.e. lysis, filtration and centrifugation) as described else-
where.9 We also confirmed the initial direct MALDI identification using
subcultured colony isolates.
AST by the Accelerate PhenoTM system
According to the manufacturer’s instructions, we performed Accelerate





system. A 500lL aliquot was transferred into the
sample vial and immediately loaded onto the system. The analysis soft-
ware Accelerate Diagnostics Host application version 1.1.0.69 was used.
AST by the VITEKV
R
2 system and the BMD method
We performed AST with the VITEKV
R
2 system according to the manufac-
turer’s instructions, using the software version 7.01 and the AST-N201,
AST-P632, AST-P586 and AST-ST01 cards for Gram-negative bacteria,
staphylococci, enterococci and streptococci, respectively. For direct AST, we
selected the VITEKV
R
2 cards according to the Gram stain results and the dir-
ect MALDI organism identification results obtained as described above. We
performed AST by the BMD method according to the 2006 ISO 20776-1 pro-
cedure, as recommended by EUCAST.26
Data analysis and discrepancy resolution
The Accelerate PhenoTM system and VITEKV
R
2 system AST results were
compared with the BMD results. We used the 2017 EUCAST standards to in-
terpret AST results for each of the following antimicrobials: amikacin, ampi-
cillin, ceftazidime, cefepime, ciprofloxacin, colistin, daptomycin,
ertapenem, erythromycin, gentamicin, linezolid, meropenem, piperacillin/
tazobactam, trimethoprim/sulfamethoxazole and vancomycin.27
Agreement of interpretative results was calculated. The discrepant results
were categorized as very major errors [VMEs (false susceptibility)], major
errors [MEs (false resistance)] and minor errors [mEs (intermediate result in-
stead of susceptible or resistant)]. Isolates showing VMEs or MEs were
retested, and if initial and repeated test results were not the same, the re-
sult of repeat testing was used for data analysis. To reproduce the condi-
tions under which blood sample aliquots were originally tested, we
performed Accelerate PhenoTM system or VITEKV
R
2 system retesting on
contrived BCs. We subcultured previously frozen isolates to prepare bacter-
ial suspensions, each containing 5%108 cfu/mL. We made appropriate
dilutions to inoculate BC broths with 1 mL (5%102 cfu) of each suspension,





system, contrived PBCs were available for AST dis-
crepancy testing.
Results
Excluding the isolates from species known to be off-panel organ-
isms (Table S1), the Accelerate PhenoTM system correctly identified
115/123 (93.5%) on-panel organisms. Seven of the eight isolates
that were not identified were from polymicrobial BCs (data not
shown). While Accelerate PhenoTM system AST results were avail-
able for 94/115 (81.7%) isolates, we included 86 (62 Gram-
negative and 24 Gram-positive) isolates from monomicrobial BCs,
resulting in 600 organism/antimicrobial test results. We compared
these results with those reported by BMD (416 susceptible, 166 re-
sistant and 18 intermediate results). For the VITEKV
R
2 system,
there were 603 organism/antimicrobial test results—with 3 corre-
sponding to the indeterminate results obtained by the Accelerate
PhenoTM system—that could be compared with those reported by
BMD (416 susceptible, 169 resistant and 18 intermediate results).
Among Gram-negative organisms, the categorical agreement was
92.7% (467/504) for the Accelerate PhenoTM system and 91.7%
(463/505) for the VITEKV
R
2 system (Table 1). Among Gram-positive
organisms, the categorical agreement was 99.0% for both the
Accelerate PhenoTM (95/96) and the VITEKV
R
2 (97/98) system
(Table 2). The overall rates of VMEs, MEs and mEs were 3.6% (6/
166), 2.2% (9/416) and 3.8% (23/600) with the Accelerate
PhenoTM system, and 2.4% (4/169), 1.0% (4/416) and 5.8% (35/
603) with the VITEKV
R
2 system (Tables 1 and 2).
As shown in Tables 1 and 2, we analysed the distributions of
agreements and errors by individual antimicrobial agent for the
species of Gram-negative and Gram-positive organisms, respect-
ively. Overall, we noted that cefepime, meropenem, amikacin,
gentamicin and ciprofloxacin showed complete categorical agree-
ment (100%) in the two systems for Enterobacter spp. (n"4) and
Serratia marcescens (n"2), as well as piperacillin/tazobactam,
ceftazidime, ertapenem, meropenem, gentamicin and ciprofloxa-
cin for Proteus spp. (n"3). The same applied to cefepime and co-
listin for Pseudomonas aeruginosa (n"8) and to meropenem and
Accelerate PhenoTM and VITEK
VR
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Table 1. Performance of the Accelerate PhenoTM system and VITEKV
R
2 systems compared with BMD for Gram-negative bacterial species (n " 62)
BMD Accelerate PhenoTM system [% (n/N)] VITEKV
R
2 system [% (n/N)]







VMEs MEs mEs VMEs MEs mEs
E. coli 19
TZP 16 1 2 94.7 (18/19) 0.0 (0/2) 0.0 (0/16) 5.3 (1/19) 89.5 (17/19) 0.0 (0/2) 0.0 (0/16) 10.5 (2/19)
cefepime 13 1 5 78.9 (15/19) 0.0 (0/5) 0.0 (0/13) 21.1 (4/19) 84.2 (16/19) 0.0 (0/5) 0.0 (0/13) 15.8 (3/19)
ceftazidime 11 3 5 89.5 (17/19) 0.0 (0/5) 0.0 (0/11) 10.5 (2/19) 84.2 (16/19) 0.0 (0/5) 0.0 (0/11) 15.8 (3/19)
ertapenem 19 0 0 100 (19/19) NA (0/0) 0.0 (0/19) 0.0 (0/19) 100 (19/19) NA (0/0) 0.0 (0/19) 0.0 (0/19)
meropenem 19 0 0 100 (19/19) NA (0/0) 0.0 (0/19) 0.0 (0/19) 94.7 (18/19) NA (0/0) 0.0 (0/19) 5.3 (1/19)
amikacin 18 1 0 94.7 (18/19) NA (0/0) 0.0 (0/18) 5.3 (1/19) 78.9 (15/19) NA (0/0) 0.0 (0/18) 21.1 (4/19)
gentamicin 16 0 3 100 (19/19) 0.0 (0/3) 0.0 (0/16) 0.0 (0/19) 94.7 (18/19) 0.0 (0/3) 0.0 (0/16) 5.3 (1/19)
ciprofloxacin 10 1 8 94.7 (18/19) 0.0 (0/8) 0.0 (0/10) 5.3 (1/19) 94.7 (18/19) 0.0 (0/8) 0.0 (0/10) 5.3 (1/19)
colistin 19 0 0 94.7 (18/19) NA (0/0) 5.3 (1/19) 0.0 (0/19) 100 (19/19) NA (0/0) 0.0 (0/19) 0.0 (0/19)
K. pneumoniae 18
TZP 6 2 10 83.3 (15/18) 10.0 (1/10) 0.0 (0/6) 11.1 (2/18) 83.3 (15/18) 0.0 (0/10) 0.0 (0/6) 16.7 (3/18)
cefepime 8 0 10 100 (17/17) 0.0 (0/9) 0.0 (0/8) 0.0 (0/17) 88.9 (16/18) 0.0 (0/10) 0.0 (0/8) 11.1 (2/18)
ceftazidime 8 0 10 100 (18/18) 0.0 (0/10) 0.0 (0/8) 0.0 (0/18) 100 (18/18) 0.0 (0/10) 0.0 (0/8) 0.0 (0/18)
ertapenem 9 0 9 94.4 (17/18) 11.1 (1/9) 0.0 (0/9) 0.0 (0/18) 100 (18/18) 0.0 (0/9) 0.0 (0/9) 0.0 (0/18)
meropenem 9 0 9 88.9 (16/18) 22.2 (2/9) 0.0 (0/9) 0.0 (0/18) 100 (18/18) 0.0 (0/9) 0.0 (0/9) 0.0 (0/18)
amikacin 15 3 0 77.8 (14/18) NA (0/0) 0.0 (0/15) 22.2 (4/18) 72.2 (13/18) NA (0/0) 13.3 (2/15) 16.7 (3/18)
gentamicin 14 0 4 94.4 (17/18) 0.0 (0/4) 0.0 (0/14) 5.6 (1/18) 72.2 (13/18) 0.0 (0/4) 0.0 (0/14) 27.8 (5/18)
ciprofloxacin 8 0 10 94.4 (17/18) 10.0 (1/10) 0.0 (0/8) 0.0 (0/18) 100 (18/18) 0.0 (0/10) 0.0 (0/8) 0.0 (0/18)
colistin 16 0 2 94.4 (17/18) 0.0 (0/2) 6.3 (1/16) 0.0 (0/18) 94.4 (17/18) 50.0 (1/2) 0.0 (0/16) 0.0 (0/18)
P. aeruginosa 8
TZP 3 0 5 100 (8/8) 0.0 (0/5) 0.0 (0/3) 0.0 (0/8) 87.5 (7/8) 0.0 (0/5) 33.3 (1/3) 0.0 (0/8)
cefepime 4 0 4 100 (8/8) 0.0 (0/4) 0.0 (0/4) 0.0 (0/8) 100 (8/8) 0.0 (0/4) 0.0 (0/4) 0.0 (0/8)
ceftazidime 3 0 5 62.5 (5/8) 0.0 (0/5) 100 (3/3) 0.0 (0/8) 87.5 (7/8) 0.0 (0/5) 33.3 (1/3) 0.0 (0/8)
meropenem 3 0 5 87.5 (7/8) 0.0 (0/5) 0.0 (0/3) 12.5 (1/8) 87.5 (7/8) 0.0 (0/5) 0.0 (0/3) 12.5 (1/8)
amikacin 3 1 4 87.5 (7/8) 0.0 (0/4) 0.0 (0/3) 12.5 (1/8) 100 (8/8) 0.0 (0/4) 0.0 (0/3) 0.0 (0/8)
gentamicin 2 0 6 100 (8/8) 0.0 (0/6) 0.0 (0/2) 0.0 (0/8) 87.5 (7/8) 16.6 (1/6) 0.0 (0/2) 0.0 (0/8)
ciprofloxacin 1 0 7 87.5 (7/8) 14.3 (1/7) 0.0 (0/1) 0.0 (0/8) 100 (8/8) 0.0 (0/7) 0.0 (0/1) 0.0 (0/8)
colistin 8 0 0 100 (8/8) NA (0/0) 0.0 (0/8) 0.0 (0/8) 100 (8/8) NA (0/0) 0.0 (0/8) 0.0 (0/8)
A. baumannii 8
meropenem 1 0 7 100 (8/8) 0.0 (0/7) 0.0 (0/1) 0.0 (0/8) 100 (8/8) 0.0 (0/7) 0.0 (0/1) 0.0 (0/8)
amikacin 2 1 5 87.5 (7/8) 0.0 (0/5) 0.0 (0/2) 12.5 (1/8) 87.5 (7/8) 0.0 (0/5) 0.0 (0/2) 12.5 (1/8)
ciprofloxacin 1 0 7 100 (8/8) 0.0 (0/7) 0.0 (0/1) 0.0 (0/8) 100 (8/8) 0.0 (0/7) 0.0 (0/1) 0.0 (0/8)
colistin 6 0 2 62.5 (5/8) 0.0 (0/2) 50.0 (3/6) 0.0 (0/8) 87.5 (7/8) 50.0 (1/2) 0.0 (0/6) 0.0 (0/8)
Enterobacter spp. 4
TZP 3 0 1 75.0 (3/4) 0.0 (0/1) 33.3 (1/3) 0.0 (0/4) 75.0 (3/4) 0.0 (0/1) 0.0 (0/3) 25.0 (1/4)
cefepime 4 0 0 100 (4/4) NA (0/0) 0.0 (0/4) 0.0 (0/4) 100 (4/4) NA (0/0) 0.0 (0/4) 0.0 (0/4)
ceftazidime 2 1 1 75.0 (3/4) 0.0 (0/1) 0.0 (0/2) 25.0 (1/4) 75.0 (3/4) 0.0 (0/1) 0.0 (0/2) 25.0 (1/4)
ertapenem 3 1 0 100 (4/4) NA (0/0) 0.0 (0/3) 0.0 (0/4) 75.0 (3/4) NA (0/0) 0.0 (0/3) 25.0 (1/4)
meropenem 4 0 0 100 (4/4) NA (0/0) 0.0 (0/4) 0.0 (0/4) 100 (4/4) NA (0/0) 0.0 (0/4) 0.0 (0/4)
amikacin 4 0 0 100 (4/4) NA (0/0) 0.0 (0/4) 0.0 (0/4) 100 (4/4) NA (0/0) 0.0 (0/4) 0.0 (0/4)
gentamicin 4 0 0 100 (4/4) NA (0/0) 0.0 (0/4) 0.0 (0/4) 100 (4/4) NA (0/0) 0.0 (0/4) 0.0 (0/4)
ciprofloxacin 4 0 0 100 (4/4) NA (0/0) 0.0 (0/4) 0.0 (0/4) 100 (4/4) NA (0/0) 0.0 (0/4) 0.0 (0/4)
colistin 4 0 0 100 (4/4) NA (0/0) 0.0 (0/4) 0.0 (0/4) 100 (4/4) NA (0/0) 0.0 (0/4) 0.0 (0/4)
Proteus mirabilis 3
TZP 3 0 0 100 (3/3) NA (0/0) 0.0 (0/3) 0.0 (0/3) 100 (3/3) NA (0/0) 0.0 (0/3) 0.0 (0/3)
cefepime 1 1 1 66.6 (2/3) 0.0 (0/1) 0.0 (0/1) 33.3 (1/3) 66.6 (2/3) 0.0 (0/1) 0.0 (0/1) 33.3 (1/3)
ceftazidime 1 0 2 100 (3/3) 0.0 (0/2) 0.0 (0/1) 0.0 (0/3) 100 (3/3) 0.0 (0/2) 0.0 (0/1) 0.0 (0/3)
ertapenem 3 0 0 100 (3/3) NA (0/0) 0.0 (0/3) 0.0 (0/3) 100 (3/3) NA (0/0) 0.0 (0/3) 0.0 (0/3)
meropenem 3 0 0 100 (3/3) NA (0/0) 0.0 (0/3) 0.0 (0/3) 100 (3/3) NA (0/0) 0.0 (0/3) 0.0 (0/3)
Continued
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ciprofloxacin for Acinetobacter baumannii (n"8), but only to erta-
penem and ceftazidime for Escherichia coli (n"19) and Klebsiella
pneumoniae (n"18), respectively. Except for trimethoprim/sulfa-
methoxazole [only tested with Staphylococcus aureus (n"10)]
and vancomycin [when tested with Enterococcus faecalis (n"5)],
all antibiotics showed 100% agreement in the two systems for the
Gram-positive species studied. Among the Gram-negative organ-
isms, the majority of errors (excluding mEs) were accounted for by
a high number of MEs for piperacillin/tazobactam, ceftazidime and
colistin when tested with the Accelerate PhenoTM system, and for
piperacillin/tazobactam, amikacin and ceftazidime when tested
with the VITEKV
R
2 system. Among the Gram-positive organisms,
there were no MEs with either system, and only one VME for E. faecalis
and vancomycin when tested with the VITEKV
R
2 system.
This study included 51 isolates resistant to one or more antimi-
crobials, for which 95.2% (158/166) of Accelerate PhenoTM system
AST results and 92.9% (157/169) of VITEKV
R
2 system AST results
were in categorical agreement with the reference method (Table 3).
When the performance of each method was stratified by type of
antimicrobial-resistant organism, categorical agreements of the
Accelerate PhenoTM and VITEKV
R
2 systems were 100% (12/12) and
92.9% (13/14) for Gram-positive bacteria and 94.8% (146/154) and
92.9% (144/155) for Gram-negative bacteria, respectively.
Discussion
Annually, there are 575000–677000 episodes of BSI and 79000–
94000 deaths estimated in North America and .1200000 epi-
sodes of BSI and 157000 deaths estimated in Europe.1 In this
alarming context, phenotypic AST using emerging technologies
would yield rapid information on the susceptibility/resistance sta-
tus of microbial pathogens directly from PBCs. Therefore, rapid AST
would not only ensure the quick administration of the right
antimicrobial agent to the patient, but would also avoid subjecting
the patient to the expense and toxicity of inefficacious antimicro-
bial therapy.28
Here we report a head-to-head comparison of AST directly from
PBCs for both the Accelerate PhenoTM and VITEKV
R
2 systems
against the gold standard BMD method, which may not be prac-
tical in most clinical microbiology laboratories. Our study extends
what has already been demonstrated on the reliability of perform-
ing direct inoculation of Gram-negative and Gram-positive organ-
isms from PBCs to achieve rapid (identification and) AST.
Importantly, we show that the Accelerate PhenoTM system per-
formance was overall equivalent (or slightly superior) to that of
conventional phenotypic AST methods, such as the VITEKV
R
2 sys-
tem. In our study, the Accelerate PhenoTM system performed reli-
ably with both Gram-negative and Gram-positive organisms, with
92.7% and 99.0% categorical agreement, respectively, and 2.2%
MEs and 3.8% mEs. However, the rate of VMEs was 3.6%, and the
six errors were only observed with Gram-negative organisms;
these findings are consistent with other studies.20–22,24 Most VMEs
were detected with Klebsiella spp. (K. pneumoniae) against various
antibiotics (piperacillin/tazobactam, ertapenem, meropenem and
ciprofloxacin) (Table 3). Direct testing by the VITEKV
R
2 system
yielded four VMEs, of which two were with colistin (one K. pneumo-
niae and one A. baumannii), one with gentamicin (P. aeruginosa)
and one with vancomycin (E. faecalis), but for this latter antimicro-
bial agent/organism combination no result was available with the
Accelerate PhenoTM system (Table 3).
In the light of the reported significant time-to-AST reduction
realized with the Accelerate PhenoTM system,21–23 it is possible to
project the impact of using the Accelerate PhenoTM system on the
effectiveness of antimicrobial therapy.29 Of the five VMEs involving
K. pneumoniae organisms tested with the Accelerate PhenoTM sys-
tem, two errors (one meropenem and one ciprofloxacin) occurred
Table 1. Continued
BMD Accelerate PhenoTM system [% (n/N)] VITEKV
R
2 system [% (n/N)]







VMEs MEs mEs VMEs MEs mEs
amikacin 1 1 1 66.6 (2/3) 0.0 (0/1) 0.0 (0/1) 33.3 (1/3) 100 (3/3) 0.0 (0/1) 0.0 (0/1) 0.0 (0/3)
gentamicin 1 0 2 100 (3/3) 0.0 (0/2) 0.0 (0/1) 0.0 (0/3) 100 (3/3) 0.0 (0/2) 0.0 (0/1) 0.0 (0/3)
ciprofloxacin 1 0 2 100 (3/3) 0.0 (0/2) 0.0 (0/1) 0.0 (0/3) 100 (3/3) 0.0 (0/2) 0.0 (0/1) 0.0 (0/3)
S. marcescens 2
TZP 1 0 1 100 (2/2) 0.0 (0/1) 0.0 (0/1) 0.0 (0/2) 50.0 (1/2) 0.0 (0/1) 0.0 (0/1) 50.0 (1/2)
cefepime 2 0 0 100 (2/2) NA (0/0) 0.0 (0/2) 0.0 (0/2) 100 (2/2) NA (0/0) 0.0 (0/2) 0.0 (0/2)
ceftazidime 2 0 0 100 (2/2) NA (0/0) 0.0 (0/2) 0.0 (0/2) 100 (2/2) NA (0/0) 0.0 (0/2) 0.0 (0/2)
ertapenem 2 0 0 100 (2/2) NA (0/0) 0.0 (0/2) 0.0 (0/2) 100 (2/2) NA (0/0) 0.0 (0/2) 0.0 (0/2)
meropenem 2 0 0 100 (2/2) NA (0/0) 0.0 (0/2) 0.0 (0/2) 100 (2/2) NA (0/0) 0.0 (0/2) 0.0 (0/2)
amikacin 2 0 0 100 (2/2) NA (0/0) 0.0 (0/2) 0.0 (0/2) 100 (2/2) NA (0/0) 0.0 (0/2) 0.0 (0/2)
gentamicin 2 0 0 100 (2/2) NA (0/0) 0.0 (0/2) 0.0 (0/2) 100 (2/2) NA (0/0) 0.0 (0/2) 0.0 (0/2)
ciprofloxacin 2 0 0 100 (2/2) NA (0/0) 0.0 (0/2) 0.0 (0/2) 100 (2/2) NA (0/0) 0.0 (0/2) 0.0 (0/2)
Total 62 332 18 155 92.7 (467/504) 3.9 (6/154) 2.7 (9/332) 4.4 (22/504) 91.7 (463/505) 1.9 (3/155) 1.2 (4/332) 6.9 (35/505)
NA, not applicable; S, susceptible; I, intermediate; R, resistant; TZP, piperacillin/tazobactam.
aValues in parentheses are the number of results with same categorical interpretation as the reference BMD results/total number of test results. The
Accelerate PhenoTM system did not provide AST results for the cefepime/K. pneumoniae combination (n"1).
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in one BC sample and two errors (one ertapenem and one merope-
nem) in another BC sample. Both of these samples were positive
for a carbapenemase-producing K. pneumoniae, as determined
molecularly (Amplex eazyplexV
R
SuperBug CRE; Amplex Diagnostics
GmbH, Gars-Bahnhof, Germany). Carbapenems are often used for
treatment escalation or combination therapy in cases of septic
shock, because they are also effective against Gram-negative
ESBL-producing pathogens.30 Unfortunately, the negative effects
of carbapenem false-susceptible phenotypic results cannot be
counteracted by supplementing them with a molecular diagnostic
test; Amplex eazyplexV
R
is, for example, a PCR-based method for
detecting blaCTX-M, blaKPC, blaOXA-48, blaNDM and blaVIM resistance
genes. Supplementing phenotypic results would require the
Amplex eazyplexV
R
test on all carbapenem-susceptible isolates;
however, the PCR-based diagnostic approach is limited to a few
frequently occurring b-lactamases and is not useful for ‘problem
pathogens’ other than E. coli and K. pneumoniae. Failure to detect
crucial carbapenemase-producing organisms could be circum-
vented through parallel phenotypic testing, which would not
shorten the time to AST result. Alternatively, the use of both the
Accelerate PhenoTM and the VITEKV
R
2 system may improve the
overall AST result but increase laboratory testing costs.
Carbapenem-resistant Enterobacteriaceae infections are difficult
to treat and salvage therapeutic options are often limited to
polymyxins (colistin and polymyxin B).31 Of the seven multidrug-
resistant A. baumannii organisms detected in our BC samples, two
were also colistin resistant with both BMD and Accelerate PhenoTM
system tests, but one of these organisms yielded a VME when
tested with the VITEKV
R
2 system. Another BC sample yielding a
VME for colistin with the VITEKV
R
2 system contained a colistin-
resistant organism (K. pneumoniae) that was PCR positive for the
blaKPC resistance gene. In one recent study, colistin testing of
Enterobacteriaceae isolates by the VITEKV
R
2 system had a VME
rate of 36%,32 which was well in excess of the1.5% rate recom-
mended by the CLSI.33 This was reproduced in our study (2/4,
50%), whereas no VMEs against colistin occurred when the same
BCs were tested with the Accelerate PhenoTM system.
The Accelerate PhenoTM system is currently FDA cleared for
monomicrobial and polymicrobial BSIs. It is noteworthy that, fol-
lowing FDA clearance, the instructions for use require identification
results to be interpreted in conjunction with Gram stain results. In
this study, according to a previously implemented BSI diagnostic
workflow,25 we performed AST testing by the VITEKV
R
2 system on
either direct PBCs or subcultured species isolates, depending on
the Gram stain information about the type of BSI (i.e. single or mul-
tiple). To make our Accelerate PhenoTM system performance
evaluation comparable with that of previous studies,21,23 we
undertook direct BC testing for AST with the Accelerate PhenoTM
Table 2. Performance of the Accelerate PhenoTM system and VITEKV
R
2 systems compared with BMD for Gram-positive bacterial species (n"24)
BMD Accelerate PhenoTM system [% (n/N)] VITEKV
R
2 system [% (n/N)]







VMEs MEs mEs VMEs MEs mEs
S. aureus 10
erythromycin 7 0 3 100 (10/10) 0.0 (0/3) 0.0 (0/7) 0.0 (0/10) 100 (10/10) 0.0 (0/3) 0.0 (0/7) 0.0 (0/10)
SXT 10 0 0 90.0 (9/10) NA (0/0) 0.0 (0/10) 10.0 (1/10) 100 (10/10) NA (0/0) 0.0 (0/10) 0.0 (0/10)
daptomycin 10 0 0 100 (10/10) NA (0/0) 0.0 (0/10) 0.0 (0/10) 100 (10/10) NA (0/0) 0.0 (0/10) 0.0 (0/10)
linezolid 10 0 0 100 (10/10) NA (0/0) 0.0 (0/10) 0.0 (0/10) 100 (10/10) NA (0/0) 0.0 (0/10) 0.0 (0/10)
vancomycin 10 0 0 100 (10/10) NA (0/0) 0.0 (0/10) 0.0 (0/10) 100 (10/10) NA (0/0) 0.0 (0/10) 0.0 (0/10)
CoNS 6
erythromycin 1 0 5 100 (5/5) 0.0 (0/4) 0.0 (0/1) 0.0 (0/5) 100 (6/6) 0.0 (0/5) 0.0 (0/1) 0.0 (0/6)
daptomycin 6 0 0 100 (6/6) NA (0/0) 0.0 (0/6) 0.0 (0/6) 100 (6/6) NA (0/0) 0.0 (0/6) 0.0 (0/6)
linezolid 6 0 0 100 (6/6) NA (0/0) 0.0 (0/6) 0.0 (0/6) 100 (6/6) NA (0/0) 0.0 (0/6) 0.0 (0/6)
vancomycin 6 0 0 100 (6/6) NA (0/0) 0.0 (0/6) 0.0 (0/6) 100 (6/6) NA (0/0) 0.0 (0/6) 0.0 (0/6)
E. faecalis 5
ampicillin 5 0 0 100 (5/5) NA (0/0) 0.0 (0/5) 0.0 (0/5) 100 (5/5) NA (0/0) 0.0 (0/5) 0.0 (0/5)
linezolid 5 0 0 100 (5/5) NA (0/0) 0.0 (0/5) 0.0 (0/5) 100 (5/5) NA (0/0) 0.0 (0/5) 0.0 (0/5)
vancomycin 4 0 1 100 (4/4) NA (0/0) 0.0 (0/4) 0.0 (0/4) 80.0 (4/5) 100 (1/1) 0.0 (0/4) 0.0 (0/5)
Enterococcus faecium 3
ampicillin 0 0 3 100 (3/3) 0.0 (0/3) NA (0/0) 0.0 (0/3) 100 (3/3) 0.0 (0/3) NA (0/0) 0.0 (0/3)
linezolid 3 0 0 100 (3/3) NA (0/0) 0.0 (0/3) 0.0 (0/3) 100 (3/3) NA (0/0) 0.0 (0/3) 0.0 (0/3)
vancomycin 1 0 2 100 (3/3) 0.0 (0/2) 0.0 (0/1) 0.0 (0/3) 100 (3/3) 0.0 (0/2) 0.0 (0/1) 0.0 (0/3)
Total 24 84 0 14 99.0 (95/96) 0.0 (0/12) 0.0 (0/84) 1.0 (1/96) 99.0 (97/98) 7.1 (1/14) 0.0 (0/84) 0.0 (0/98)
NA, not applicable; S, susceptible; I, intermediate; R, resistant. SXT, trimethoprim/sulfamethoxazole.
aValues in parentheses are the numbers of results with same categorical interpretation as the reference BMD results over the total numbers of test
results. The Accelerate PhenoTM system did not provide AST results for the following antibiotic-pathogen combinations: erythromycin/coagulase-
negative Staphylococcus sp. (n"1) and vancomycin/E. faecalis (n"1).
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system blinded to Gram stain results. Consequently, Accelerate
PhenoTM system results for polymicrobial BCs (eight species organ-
isms evaluable in total) were not included in the present analysis.
Because the Accelerate PhenoTM system AST performance for
polymicrobial BSIs may not be optimal,22,23 a better use of the
Accelerate PhenoTM system could be to integrate the system with
standard microbiological procedures, such as the microscopic
examination of clinical samples in a preliminary diagnostic work-
flow step.
Potential shortcomings of this study include: (i) the limited
number of some organisms tested (e.g. only two S. marcescens
isolates) and some resistance phenotypes, such as to vancomycin,
linezolid and daptomycin; and (ii) the lack of complex resistance
phenotypes, such as MDR MRSA [e.g. heterogeneous vancomycin-
intermediate S. aureus (hVISA, VISA)]. In our study, there were five
MRSA organisms correctly detected with the VITEKV
R
2 system by
oxacillin testing, which is not included in the Accelerate PhenoTM
system panel. However, the Accelerate PhenoTM system was able
to identify the same MRSA organisms using the cefoxitin-induction
assay.19 Further, although Accelerate PhenoTM system results for
all organism/antimicrobial combinations were evaluated for re-
search purposes only, we did not use the 2016 EUCAST break-
points, which are currently employed by the system to
automatically interpret AST results. Hence, to mimic real-time ex-
perience with the Accelerate PhenoTM system, we manually inter-
preted MIC data using the 2017 EUCAST breakpoints.
Consequently, additional AST testing would have been necessary
in a number of cases, particularly for the Gram-positive organisms,
for which comparison between the Accelerate PhenoTM and
VITEKV
R
2 systems was possible for only five antimicrobials. Finally,
this study does not address the possible implications of rapid
AST, such as the effect on laboratory workflow (e.g. time savings,
greater technologist autonomy, etc.), or factors outside the labora-
tory (e.g. time to effective therapy, patient care and outcome,
etc.).34 Future studies will explore these issues in detail.
In conclusion, the Accelerate PhenoTM system provides rapid
and accurate AST results for the majority of organism/antimicro-
bial combinations, which involve the most common bacterial
pathogens found routinely in PBCs. It also performs comparably,
and in some cases is superior, to the conventional phenotypic
VITEKV
R
2 system. Additional studies including a larger number of
Gram-positive organisms, Gram-negative organisms and especial-
ly samples containing multiple organisms are necessary before
considering the Accelerate PhenoTM system as the standard of
care in patients with BSIs.
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E. coli (9) 23 21 (91.3) 2 mEs with cefepime 23 20 (86.9) 2 mEs with cefepime,
1 mE with ceftazidime.
K. pneumoniae (11) 63 58 (92.0) 1 VME with TZP, 64 60 (93.7) 1 VME with colistin,
1 VME with ertapenem, 1 mE with TZP,
2 VMEs with meropenem, 2 mEs with cefepime.
1 VME with ciprofloxacin.
P. aeruginosa (8) 36 35 (97.2) 1 VME with ciprofloxacin. 36 34 (94.4) 1 VME with gentamicin,
1 mE with meropenem.
A. baumannii (7) 21 21 (100) no errors 21 20 (95.2) 1 VME with colistin
Enterobacter species (1) 2 2 (100) no errors 2 2 (100) no errors
Proteus mirabilis (2) 8 8 (100) no errors 8 8 (100) no errors
S. marcescens (1) 1 1 (100) no errors 1 0 (0.0) 1 mE with TZP
S. aureus (3) 3 3 (100) no errors 3 3 (100) no errors
CoNS (5) 4 4 (100) no errors 5 5 (100) no errors
E. faecalis (1) 0 – – 1 0 (0.0) 1 VME with vancomycin
Enterococcus faecium (3) 5 5 (100) no errors 5 5 (100) no errors
Total (51) 166 158 (95.2) 6 VMEs, 2 mEs 169 157 (92.9) 4 VMEs, 8 mEs
VME, very major error; mE, minor error; TZP, piperacillin/tazobactam.
aNot including three indeterminate AST results for one isolate of K. pneumoniae, one isolate of coagulase-negative Staphylococcus species and one
isolate of E. faecalis.
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